Skip to main content
Erschienen in: Annals of Hematology 9/2014

01.09.2014 | Original Article

Is it really possible to cure hairy cell leukemia patients only with frontline therapy?

verfasst von: Pier Luigi Zinzani, Vittorio Stefoni, Alessandro Broccoli, Cinzia Pellegrini, Letizia Gandolfi, Beatrice Casadei, Roberto Maglie, Stefano Pileri, Lisa Argnani

Erschienen in: Annals of Hematology | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Hairy cell leukemia (HCL) patients could have an excellent prognosis with adequate treatment. Treatments are not generally curative but are extremely effective in inducing long-lasting clinical remissions. An observational retrospective study was conducted on a single-center registry of 144 patients with a median follow-up of 11.5 years, focusing on long-lasting continuous first complete remissions (CR) wondering if patients can be cured only with front-line approach. CR for more than 5 years after first-line therapy were found in 22.2 % cases. The median duration of response was 9.8 years, while for relapsed patients, the first response had a median duration of 2.4 years. Three different subsets of long-lasting first CR were identified: 15 patients are between 5 and 10 years with a median duration of CR of 6.5 years; 7 patients are between 10 and 15 years with a median duration of CR of 12.3 years; and 10 patients present a follow-up superior to 15 years with a median duration of CR of 20.0 years. There is a need for continuous study in this field to better define the optimal therapeutic regimen and, in particular, the biological issues since at least 20–25 % of HCL patients can be cured with only one treatment.
Literatur
1.
Zurück zum Zitat Golde DW, Weiss MA (2000) Hairy cell leukemia, an historical perspective. In: Tallman M, Polliack A (eds) Hairy cell leukemia. Harwood Academic, The Netherlands, pp 1–8 Golde DW, Weiss MA (2000) Hairy cell leukemia, an historical perspective. In: Tallman M, Polliack A (eds) Hairy cell leukemia. Harwood Academic, The Netherlands, pp 1–8
2.
Zurück zum Zitat Golomb HM, Catovsky D, Golde DW (1978) Hairy cell leukaemia: a clinical review based on 71 cases. Ann Intern Med 81:677–683CrossRef Golomb HM, Catovsky D, Golde DW (1978) Hairy cell leukaemia: a clinical review based on 71 cases. Ann Intern Med 81:677–683CrossRef
3.
Zurück zum Zitat Berman E, Heller G, Kempin S, Gee T, Tran LL, Clarkson B (1990) Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood 75:839–845PubMed Berman E, Heller G, Kempin S, Gee T, Tran LL, Clarkson B (1990) Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood 75:839–845PubMed
4.
Zurück zum Zitat Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WE, Cassileth PA, Habermann T, Golomb H (1995) Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 13:974–982PubMed Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WE, Cassileth PA, Habermann T, Golomb H (1995) Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 13:974–982PubMed
5.
Zurück zum Zitat Federico M, Frassoldati A, Lamparelli T, Foà R, Brugiatelli M, Annino L, Baldini L, Capnist G, Chisesim T, di Celle PF (1994) Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL. Ann Oncol 5:725–731PubMed Federico M, Frassoldati A, Lamparelli T, Foà R, Brugiatelli M, Annino L, Baldini L, Capnist G, Chisesim T, di Celle PF (1994) Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL. Ann Oncol 5:725–731PubMed
6.
Zurück zum Zitat Flandrin G, Sigaux F, Sebahoun G, Bouffette P (1984) Hairy cell leukemia: clinical presentation and follow-up of 211 patients. Semin Oncol 11:458–471PubMed Flandrin G, Sigaux F, Sebahoun G, Bouffette P (1984) Hairy cell leukemia: clinical presentation and follow-up of 211 patients. Semin Oncol 11:458–471PubMed
7.
Zurück zum Zitat Spiers AS, Moore D, Cassileth PA, Harrington DP, Cummings FJ, Neiman RS, Bennett JM, O'Connell MJ (1987) Remissions in hairy-cell leukemia with pentostatin (20-deoxycoformycin). N Engl J Med 316:825–830PubMedCrossRef Spiers AS, Moore D, Cassileth PA, Harrington DP, Cummings FJ, Neiman RS, Bennett JM, O'Connell MJ (1987) Remissions in hairy-cell leukemia with pentostatin (20-deoxycoformycin). N Engl J Med 316:825–830PubMedCrossRef
8.
Zurück zum Zitat Piro LD, Carrera CJ, Carson DA, Beutler E (1990) Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322:1117–1121PubMedCrossRef Piro LD, Carrera CJ, Carson DA, Beutler E (1990) Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322:1117–1121PubMedCrossRef
9.
Zurück zum Zitat Dearden CE, Matutes E, Hilditch BL, Swansbury GJ, Catovsky D (1999) Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin for cladribine. Br J Haematol 106:515–519PubMedCrossRef Dearden CE, Matutes E, Hilditch BL, Swansbury GJ, Catovsky D (1999) Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin for cladribine. Br J Haematol 106:515–519PubMedCrossRef
10.
Zurück zum Zitat Chadha P, Rademaker AW, Mendiratta P, Kim B, Evanchuk DM, Hakimian D, Peterson LC, Tallman MS (2005) Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 106:241–246PubMedCrossRef Chadha P, Rademaker AW, Mendiratta P, Kim B, Evanchuk DM, Hakimian D, Peterson LC, Tallman MS (2005) Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 106:241–246PubMedCrossRef
11.
Zurück zum Zitat Maloisel F, Benboubker L, Gardembas M, Coiffier B, Divine M, Sebban C, Blanc M, Abgrall JF, Lederlin P, Harousseau JL, Blaise AM, Grosbois B, Morice P, Ghandour C, Castaigne S (2003) Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 17:45–51PubMedCrossRef Maloisel F, Benboubker L, Gardembas M, Coiffier B, Divine M, Sebban C, Blanc M, Abgrall JF, Lederlin P, Harousseau JL, Blaise AM, Grosbois B, Morice P, Ghandour C, Castaigne S (2003) Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 17:45–51PubMedCrossRef
12.
Zurück zum Zitat Rafel M, Cervantes F, Beltran JM, Zuazu F, Hernández Nieto L, Rayón C, García Talavera J, Montserrat E (2000) Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer 88:352–357PubMedCrossRef Rafel M, Cervantes F, Beltran JM, Zuazu F, Hernández Nieto L, Rayón C, García Talavera J, Montserrat E (2000) Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer 88:352–357PubMedCrossRef
13.
Zurück zum Zitat Zinzani PL, Tani M, Marchi E, Stefoni V, Alinari L, Musuraca G, Gabriele A, Pileri S, Baccarani M (2004) Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 89:309–313PubMed Zinzani PL, Tani M, Marchi E, Stefoni V, Alinari L, Musuraca G, Gabriele A, Pileri S, Baccarani M (2004) Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 89:309–313PubMed
14.
Zurück zum Zitat Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison R, Corbett W, Cassileth P, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson B, Grever MR (2000) Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96:2981–2986PubMed Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison R, Corbett W, Cassileth P, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson B, Grever MR (2000) Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96:2981–2986PubMed
15.
Zurück zum Zitat Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V (2004) An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 18:1476–1481PubMedCrossRef Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V (2004) An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 18:1476–1481PubMedCrossRef
16.
Zurück zum Zitat Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A, Wotherspoon A, Swansbury J, Dearden C, Catovsky D (2005) Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 104:2442–2448PubMedCrossRef Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A, Wotherspoon A, Swansbury J, Dearden C, Catovsky D (2005) Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 104:2442–2448PubMedCrossRef
17.
Zurück zum Zitat Zinzani PL, Pellegrini C, Stefoni V, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M (2010) Hairy cell leukaemia: evaluation of the long-term outcome in 121 patients. Cancer 116:4788–4792PubMedCrossRef Zinzani PL, Pellegrini C, Stefoni V, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M (2010) Hairy cell leukaemia: evaluation of the long-term outcome in 121 patients. Cancer 116:4788–4792PubMedCrossRef
18.
Zurück zum Zitat Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZ, Johnson SA, O’Connor NT, Haynes A, Osuji N, Forconi F, Lauria F, Catovsky D (2009) Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 145:733–740PubMedCrossRef Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZ, Johnson SA, O’Connor NT, Haynes A, Osuji N, Forconi F, Lauria F, Catovsky D (2009) Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 145:733–740PubMedCrossRef
19.
Zurück zum Zitat di Celle PF, Reato G, Raspadori D, Carbone A, Rondelli D, Lauria F, Foà R (1994) Molecular evaluation of clonal remission in hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. Leuk Lymphoma 14(Suppl 1):139–142PubMed di Celle PF, Reato G, Raspadori D, Carbone A, Rondelli D, Lauria F, Foà R (1994) Molecular evaluation of clonal remission in hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. Leuk Lymphoma 14(Suppl 1):139–142PubMed
20.
Zurück zum Zitat Ellison D, Sharpe R, Robbins B, Spinosa JC, Leopard JD, Saven A, Piro LD (1994) Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukaemia. Blood 84:4310–4315PubMed Ellison D, Sharpe R, Robbins B, Spinosa JC, Leopard JD, Saven A, Piro LD (1994) Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukaemia. Blood 84:4310–4315PubMed
21.
Zurück zum Zitat Filleul B, Delannoy A, Ferrant A, Zenebergh A, Van Daele S, Bosly A, Doyen C, Mineur P, Glorieux P, Driesschaert P (1994) A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 8:1153–1156PubMed Filleul B, Delannoy A, Ferrant A, Zenebergh A, Van Daele S, Bosly A, Doyen C, Mineur P, Glorieux P, Driesschaert P (1994) A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 8:1153–1156PubMed
22.
Zurück zum Zitat Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukemia (1987) Leukemia 1:405 Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukemia (1987) Leukemia 1:405
23.
Zurück zum Zitat Dearden CE, Else M, Catovsky D (2011) Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma 52(S2):21–24PubMedCrossRef Dearden CE, Else M, Catovsky D (2011) Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma 52(S2):21–24PubMedCrossRef
24.
Zurück zum Zitat Golomb HM, Vardiman JW (1983) Response to splenectomy in 65 patients with hairy cell leukaemia: an evaluation of spleen weight and bone marrow involvement. Blood 61:349–352PubMed Golomb HM, Vardiman JW (1983) Response to splenectomy in 65 patients with hairy cell leukaemia: an evaluation of spleen weight and bone marrow involvement. Blood 61:349–352PubMed
25.
Zurück zum Zitat Quesada JR, Reuben JR, Manning JT, Hersh EM, Gutterman JU (1984) Alpha interferon for the induction of remission in hairy cell leukaemia. N Engl J Med 310:15–18PubMedCrossRef Quesada JR, Reuben JR, Manning JT, Hersh EM, Gutterman JU (1984) Alpha interferon for the induction of remission in hairy cell leukaemia. N Engl J Med 310:15–18PubMedCrossRef
26.
Zurück zum Zitat Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K (1985) Treatment of hairy cell leukaemia with recombinant alpha 2 interferon. Blood 65:644–648PubMed Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K (1985) Treatment of hairy cell leukaemia with recombinant alpha 2 interferon. Blood 65:644–648PubMed
27.
Zurück zum Zitat Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy- resistant hairy-cell leukemia. N Engl J Med 345:241–247PubMedCrossRef Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy- resistant hairy-cell leukemia. N Engl J Med 345:241–247PubMedCrossRef
28.
Zurück zum Zitat Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, Pastan I (2005) Phase I trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 23:6719–6729PubMedCrossRef Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, Pastan I (2005) Phase I trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 23:6719–6729PubMedCrossRef
29.
Zurück zum Zitat Ravandi F, Jorgensen JF, O’Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM (2006) Eradication of minimal residual disease in hairy cell leukemia. Blood 107:4658–4662PubMedCrossRef Ravandi F, Jorgensen JF, O’Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM (2006) Eradication of minimal residual disease in hairy cell leukemia. Blood 107:4658–4662PubMedCrossRef
30.
Zurück zum Zitat Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T (2012) BRAF inhibition in refractory hairy cell leukaemia. N Engl J Med 366:2038–2040PubMedCrossRef Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T (2012) BRAF inhibition in refractory hairy cell leukaemia. N Engl J Med 366:2038–2040PubMedCrossRef
31.
Zurück zum Zitat Peyrade F, Re D, Ginet C, Gastaud L, Allegra M, Ballotti R, Thyss A, Zenz T, Auberger P, Robert G (2013) Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica 98:20–22CrossRef Peyrade F, Re D, Ginet C, Gastaud L, Allegra M, Ballotti R, Thyss A, Zenz T, Auberger P, Robert G (2013) Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica 98:20–22CrossRef
32.
Zurück zum Zitat Juliusson G, Samuelsson H, Swedish lymphoma registry (2011) Hairy cell leukaemia: epidemiology, pharmacokinetics of cladribine, and long-term follow up of subcutaneous therapy. Leuk Lymphoma 52(S2):46–49PubMedCrossRef Juliusson G, Samuelsson H, Swedish lymphoma registry (2011) Hairy cell leukaemia: epidemiology, pharmacokinetics of cladribine, and long-term follow up of subcutaneous therapy. Leuk Lymphoma 52(S2):46–49PubMedCrossRef
Metadaten
Titel
Is it really possible to cure hairy cell leukemia patients only with frontline therapy?
verfasst von
Pier Luigi Zinzani
Vittorio Stefoni
Alessandro Broccoli
Cinzia Pellegrini
Letizia Gandolfi
Beatrice Casadei
Roberto Maglie
Stefano Pileri
Lisa Argnani
Publikationsdatum
01.09.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 9/2014
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-014-2081-5

Weitere Artikel der Ausgabe 9/2014

Annals of Hematology 9/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.